SCHEMBL274223

SCHEMBL274223

Cc1ncc(-c2ccnc(Nc3ccc(C(=O)Nc4ccccc4N)cc3)n2)n1C(C)C

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 15/20 0.72
KCNH2 Q12809 7/20 0.70
HDAC1 Q13547 1/20 0.64
CDK1 P06493 5/20 0.62
CDK4 P11802 3/20 0.59
CDKL1 Q00532 1/20 0.59
CCNT1 O60563 1/20 0.58
CCNB1 P14635 1/20 0.58
CSNK2A2 P19784 1/20 0.58
CCNA2 P20248 1/20 0.58
CCND1 P24385 1/20 0.58
CCNE1 P24864 1/20 0.58
CCND3 P30281 1/20 0.58
MAPK8 P45983 1/20 0.58
MAPK9 P45984 1/20 0.58
CSNK1A1 P48729 1/20 0.58
CSNK1D P48730 1/20 0.58
GSK3A P49840 1/20 0.58
GSK3B P49841 1/20 0.58
CDK7 P50613 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL273135 0.91 CDK2 (0.60) CDK2KCNH2HDAC1CDK1CDK4
SCHEMBL272861 0.90 CDK2 (0.57) CDK2KCNH2HDAC1CDK1CDK4
SCHEMBL273533 0.88 CDK2 (0.68) CDK2KCNH2CDK1CDK4CDKL1
SCHEMBL272487 0.88 CDK2 (0.55) CDK2KCNH2HDAC1CDK1JAK2
SCHEMBL273627 0.87 CDK2 (0.66) CDK2KCNH2CDK1CDK4CDKL1
SCHEMBL273757 0.85 CDK2 (0.65) CDK2KCNH2CDK1CDK4CDKL1
SCHEMBL272434 0.84 CDK2 (0.60) CDK2KCNH2HDAC1CDK1CDK4
SCHEMBL274821 0.84 CDK2 (0.85) CDK2KCNH2CDK1CDK4CDKL1
SCHEMBL4521927 0.84 CDK2 (1.00) CDK2KCNH2CDK1CDK4CDKL1
SCHEMBL274399 0.84 CDK2 (0.53) CDK2KCNH2HDAC1CDK1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134000-B2 Imidazolyl pyrimidine inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-03-13 US claimed
JP-2011528039-A 2011-11-10 JP claimed
WO-2010009139-A2 IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS GILEAD COLORADO, INC. (US) 2010-01-21 WO claimed
US-20100009990-A1 IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-14 US claimed
US-8134000-B2 Imidazolyl pyrimidine inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-03-13 US disclosed
US-8134000-B2 Imidazolyl pyrimidine inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-03-13 US disclosed
US-8134000-B2 Imidazolyl pyrimidine inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-03-13 US disclosed
WO-2010009139-A2 IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS GILEAD COLORADO, INC. (US) 2010-01-21 WO disclosed
WO-2010009139-A2 IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS GILEAD COLORADO, INC. (US) 2010-01-21 WO disclosed
US-20100009990-A1 IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-14 US disclosed
US-20100009990-A1 IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-14 US disclosed
US-20100009990-A1 IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009990-A1 IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS HDAC1, CDK9, CDK2 CDK2 3/4885KCNH2 3847/4885HDAC1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.